Alzheimer's disease features amyloid-beta plaques and tau tangles, driving neuronal loss and cognitive decline.
Stem cell therapy for Alzheimer's Disease is an investigational regenerative approach that uses living cells — such as mesenchymal stem cells and exosomes — to target the disease process. MSC and exosome protocols target neuro-inflammation and synaptic support in early-stage cognitive decline, as an adjunct to standard care. It is not an approved cure for Alzheimer's Disease: results come from early-phase clinical trials and clinic case series, not large randomised studies, and the realistic goal is slowed progression or symptom improvement rather than reversal.
New to Alzheimer's Disease? Read our plain-English guide to the 7 stages of Alzheimer's Disease.
Alzheimer's disease features amyloid-beta plaques and tau tangles, driving neuronal loss and cognitive decline. Stem-cell approaches address several pathways: placental mesenchymal stem cells are studied for neuroprotection — secreting anti-inflammatory and growth factors that may slow neuronal death — while exosomes derived from stem cells are explored as carriers for therapeutic molecules across the blood-brain barrier and as modulators of amyloid and tau biology. The rationale builds on evidence that stem-cell products reduce neuroinflammation and may support hippocampal neuroplasticity. Reversing established pathology and achieving adequate brain delivery remain unsolved; early trials are small and heterogeneous, with uncertain durability.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €18,900–€21,000 (bookinghealth.com) |
| 研究的主要细胞类型 | MSCs from Amniotic Membrane, Exosomes |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 41 · 9 recruiting now |
For the clinic's own description, see how Stem Plus describes its Alzheimer's Disease programme ↗.
Forty-one registered trials and 9 recruiting studies investigate stem-cell therapy in Alzheimer's. Small cohorts describe modest cognitive-score changes over 6–12 months; most are uncontrolled. Some show shifts in cerebrospinal-fluid or PET amyloid/tau markers, with less consistent functional gains. No trial has prevented decline or shown reversal of neuronal loss. Approved amyloid-targeting antibodies (lecanemab, aducanumab) show modest slowing of early decline — stem-cell benefit is not proven to match them.
Depending on assessment, a Alzheimer's Disease protocol may draw on:
Indicative European costs are roughly €3,500–€7,000 per course; exosome-based protocols can reach €5,000–€8,000 due to manufacturing complexity. Pre/post neuroimaging (MRI, PET) adds further expense, and multi-dose protocols are common. For context, approved Alzheimer's drugs range from inexpensive symptomatic agents to costly antibody infusions — the stem-cell figure is indicative and less evidence-backed.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Alzheimer's Disease cost-by-country breakdown, or compare the best countries for Alzheimer's Disease →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Alzheimer's Disease.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Last reviewed 2026-07-23; see our editorial standards. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估